DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of “Buy” from Analysts

DICE Therapeutics, Inc. (NASDAQ:DICEGet Rating) has been given a consensus rating of “Buy” by the six research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $43.33.

DICE has been the subject of a number of research analyst reports. Stifel Nicolaus initiated coverage on DICE Therapeutics in a research report on Tuesday, September 6th. They issued a “buy” rating and a $37.00 target price for the company. Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research report on Wednesday, September 14th. They issued an “overweight” rating and a $36.00 target price for the company. Finally, HC Wainwright initiated coverage on DICE Therapeutics in a research report on Monday, July 18th. They issued a “buy” rating and a $40.00 target price for the company.

DICE Therapeutics Trading Down 0.2 %

Shares of NASDAQ DICE opened at $19.98 on Wednesday. The stock has a 50 day simple moving average of $18.22 and a 200-day simple moving average of $17.68. The company has a market cap of $763.46 million and a PE ratio of -5.23. DICE Therapeutics has a 12-month low of $12.64 and a 12-month high of $40.50.

Institutional Trading of DICE Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Cutler Group LP acquired a new position in shares of DICE Therapeutics in the first quarter worth $279,000. Virtus ETF Advisers LLC acquired a new position in shares of DICE Therapeutics in the fourth quarter worth $169,000. Northpond Ventures LLC acquired a new position in shares of DICE Therapeutics in the fourth quarter worth $83,343,000. Deep Track Capital LP acquired a new position in shares of DICE Therapeutics in the fourth quarter worth $33,941,000. Finally, TD Asset Management Inc. increased its stake in shares of DICE Therapeutics by 16.2% in the fourth quarter. TD Asset Management Inc. now owns 47,426 shares of the company’s stock worth $1,200,000 after acquiring an additional 6,600 shares during the last quarter. 95.42% of the stock is owned by institutional investors and hedge funds.

About DICE Therapeutics

(Get Rating)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Featured Stories

Analyst Recommendations for DICE Therapeutics (NASDAQ:DICE)

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.